Blood:CCND1和STAT3参与套细胞淋巴瘤中SOX11的表达调控

2019-01-02 MedSci MedSci原创

中心点:CCND1与HDAC1/2结合,阻碍其招募至SOX11启动子,从而增强组蛋白乙酰化和SOX11的转录。STAT3通过与SOX11基因的启动子和增强子直接相互作用来抑制SOX11的转录。摘要:神经转录因子SOX11在经典套细胞淋巴瘤(MCL)中常高表达,但在较为惰性的MCL亚型中不表达。虽然SOX11是该难治疗的恶性肿瘤的一个重要的预后标志物,但其异常表达的机制还基本不明确。Atish Mo

中心点:

CCND1与HDAC1/2结合,阻碍其招募至SOX11启动子,从而增强组蛋白乙酰化和SOX11的转录。

STAT3通过与SOX11基因的启动子和增强子直接相互作用来抑制SOX11的转录。

摘要:

神经转录因子SOX11在经典套细胞淋巴瘤(MCL)中常高表达,但在较为惰性的MCL亚型中不表达。虽然SOX11是该难治疗的恶性肿瘤的一个重要的预后标志物,但其异常表达的机制还基本不明确。

Atish Mohanty等人发现在多种人类CL细胞系中,CCND1异位表达导致SOX11的转录增加,这与乙酰化的组蛋白H3K9和H3K14(H3K9/14Ac)增加相关。通过RNA干扰敲除或HDAC抑制剂vorinostat抑制HDAC1或HDAC2后,也可观察到H3K9/14Ac和SOX11表达增加。

在机制上,研究人员发现CCND1与SOX11位点的HDAC1和HDAC2相互作用并相互隔离,导致SOX11上调。此外,本研究还发现在MCL细胞系中、原发性肿瘤和患者来源异种移植物中,磷酸化的Y705 (pY705) STAT3与SOX11表达存在潜在负相关。

在功能上,通过抑制上游的Janes激酶(JAK)1/2或通过敲除STAT3来失活STAT3,可增加SOX11的表达,而白介素21(IL21)诱导的STAT3激活或过表达激活形态的STAT3则可降低SOX11的表达。此外,在SOX11阳性的MCL细胞中,通过RNA干扰或通过IL21治疗间接直接靶向SOX11可诱导细胞毒性。

总而言之,本研究表明CCND1和STAT3参与SOX1表达的调控,为MCL治疗提供新的方向。

原始出处:

Atish Mohanty,et al.Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.Blood 2018 :blood-2018-05-851667; doi: https://doi.org/10.1182/blood-2018-05-851667 

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-06-09 一叶知秋
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-01-03 李研东
  5. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-01-03 龙胆草

    学习谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-01-02 wxl882001

    了解一下

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1782676, encodeId=e1101e826760d, content=<a href='/topic/show?id=87d5422198' target=_blank style='color:#2F92EE;'>#CCND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4221, encryptionId=87d5422198, topicName=CCND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Jun 09 01:04:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984309, encodeId=02be1984309d7, content=<a href='/topic/show?id=4cfa902e9fe' target=_blank style='color:#2F92EE;'>#表达调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90279, encryptionId=4cfa902e9fe, topicName=表达调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Jul 25 01:04:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702544, encodeId=53fd1e02544c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Aug 16 05:04:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348969, encodeId=0a01134896993, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Jan 03 16:04:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357055, encodeId=436835e055b6, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 03 09:14:06 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356994, encodeId=1c06356994df, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 02 18:24:37 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356985, encodeId=4b0735698558, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jan 02 12:16:13 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-01-02 smartxiuxiu

    0

相关资讯

2018 BSH指南:套细胞淋巴瘤的管理

2018年5月,英国血液病学学会(BSH)发布了套细胞淋巴瘤的管理指南,指南主要目的是面向临床医生针对套细胞淋巴瘤患者的管理提出指导建议,该指南是对2012年指南的更新,新版指南涵盖了套细胞淋巴瘤的新的治疗观点,涉及移植数据,病理学进展尤其是分子病理学和PET/CT在肿瘤分期和治疗反应评估中的应用。

Blood:来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗,缓解率高且持久

中心点:来那度胺联合利妥昔单抗作为MCL的诱导和维持疗法可获得持久的MRD阴性的完全缓解。长期治疗相关的不良事件通常是非累积性的,且仍可控。摘要:研究人员开展了一多中心的2期试验,招募了38位未治疗过的MCL患者,中位年龄65岁,套细胞淋巴瘤国际预后指数(MIPI)评分分布在低、中、高风险(分别占34%、34%和32%),予以来那度胺联合利妥昔单抗(LR)作为初始治疗,包括诱导和维持。治疗持续至病

Blood:套细胞淋巴瘤

套细胞淋巴瘤(MCL)是一种罕见的非霍奇金淋巴瘤亚型,鉴于其预后不良,确诊时常采用化疗免疫联合疗法。现已发现其更多的惰性特点,如患者推迟初始治疗而不影响存活期。2016年世界卫生组织更新的分类描述了两种主要亚型,典型MCL和白血病性非淋巴结性MCL,各有其独特的分子特征和临床表现。目前尚无MCL的标准疗法,以利妥昔单抗和阿糖胞苷为主的强效化疗免疫方案,联合自体干细胞移植进行巩固、利妥昔单抗维持是年

Lancet oncol:VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期

LYM-3002研究,在不适合进行移植的未治疗过的新确诊的套细胞淋巴瘤患者中对比硼替佐米联合利妥昔单抗、环磷酰胺、阿霉素和强的松(VR-CAP)和利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松(R-CHOP)两种一线疗法的疗效和安全性。现研究人员对达到主要的无进展存活期结点后,长期随访阶段患者的最终总体存活期和安全预后结果进行报告。LYM-3002是在28个国家的128个临床中心开展的一项随机化的

Lancet:acalabrutinib用于治疗复发性/难治性套细胞淋巴瘤的效果和安全性。

Bruton酪氨酸激酶是一种经过评估临床验证的套细胞淋巴瘤的治疗靶点。Acalabrutinib(ACP-196)是高选择性的、Bruton酪氨酸激酶强效抑制剂。Michael Wang等人进行一非盲的2期研究,评估acalabrutinib用于复发性/难治性套细胞淋巴瘤患者的治疗效果和安全性。研究人员招募复发性/难治性套细胞淋巴瘤患者,予以口服acalabrutinib(100mg 2次/日),

Blood:SOX11可放大BCR信号,促进MCL样肿瘤细胞进展

中心点:B细胞特异性过表达SOX11可促进B1a B细胞致瘤性增殖,并驱动出现MCL样表型。SOX11过表达与通过BCR信号增强的信号通路相关,BCR信号可被药物BTK抑制剂逆转。摘要:套细胞(MCL)的特点是B细胞受体(BCR)信号增强,应用BTK抑制剂治疗MCL患者可获得积极的治疗效果。但对导致MCL发生BCL信号增强的潜在机制尚不明了,尤其是在其他的淋巴瘤中,BCR信号上游调控子(如CD79